Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

102.63 -2.64 (-2.51%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Novo Nordisk Unusual Options Activity
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future? 
Via The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering. 
Via Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
Looking At Novo Nordisk's Recent Unusual Options Activity
Via Benzinga
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
The companies are well-known for their obesity treatments and could reach a $1 trillion market cap before carmaker Tesla. 
Via Investor's Business Daily
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, the company plans to list on Nasdaq under the symbol BIOA. Their lead drug,... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is... 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly Launches Discounted Mounjaro And Zepbound As Fight Against Compounded Imitations Escalates Amid Ongoing FDA Shortage Status Debate
Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepbound. 
Via Benzinga
Exposures Product Safety
Market Thoughts This Labor Day Weekend
For this long weekend, I am offering you food for thought. In the overall macro theme, I am sticking to this for time being: Stagflation - The Fed can’t fix it with a huge reduction in rates, that will... 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Ozempic: Unexpected Anti-Aging Miracle Drug? Researchers Reveal Surprising Potential
Ozempic may offer unexpected anti-aging benefits, potentially improving health and reducing mortality rates, according to new research. 
Via Benzinga
3 No-Brainer Stocks to Buy in September
There's at least one key common denominator here: tremendous growth prospects. 
Via The Motley Fool
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now
This competitive showdown just saw one of the players hit a couple of bumps. 
Via The Motley Fool
Judge's Early Ruling May Shape Outcome In Ozempic, Wegovy Lawsuits
A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo Nordisk and Eli Lilly, focusing on the diagnosis of gastroparesis and the... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials published by The Lancet. While not approved for heart failure outcomes in the US,... 
Via Benzinga
This New Finding About Ozempic and Wegovy Could Hurt Novo Nordisk's Stock
The addressable market for the treatments could potentially contract significantly. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Is Eli Lilly Stock a No-Brainer Buy After the Company's Brilliant Zepbound Move?
Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem. 
Via The Motley Fool
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space. 
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
The single-dose vials will also increase supply, the drug giant says. 
Via Investor's Business Daily
Ozempic Could Have a Terrible Side Effect. Is Novo Nordisk in Trouble?
Shareholders don't have too much to fear -- yet. 
Via The Motley Fool
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
Eli Lilly’s Path to the Next Trillion Market Capitalization
Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes. 
Via MarketBeat
Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices
Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senator Sanders and experts remain critical as a Senate hearing looms next... 
Via Benzinga
This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk. 
Via The Motley Fool
2 No-Brainer Healthcare Stocks to Buy With $1,000
There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.